ESMO 2021

REVIEW UroToday

Viewing 1-20 of 137 articles

ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer (mHSPC)

ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer (mCSPC)

ESMO 2021: PSMAddition: A Phase III Trial to Compare Treatment with 177Lu-PSMA-617 plus Standard of Care (SOC) Versus SOC Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2021: A First-in-Human Study of FOR46 in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)

ESMO 2021: PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment with a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients with mCRPC

ESMO 2021: PRIMORDIUM - A Randomized, International, Trial-in-Progress of Adding Apalutamide to Radiotherapy and an LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer

ESMO 2021: Antibiotic Therapy and Outcome from Nivolumab in Metastatic Renal Cell Carcinoma (mRCC) Patients: Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study

ESMO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ESMO 2021: High- vs Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer (NABUCCO Cohort 2)

ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC)

ESMO 2021: Cisplatin (Cis)-Related Immunomodulation and Efficacy with Atezolizumab + Cis- vs Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer (mUC)

ESMO 2021: AI, Targeted Data and Predictive Analytics to Monitor and Proactively Manage Patient Outcomes and Validate the Quality and Benefit of Cancer Care

ESMO 2021: How Patients Can Support the Qualitative Empirical Data and Strengthen Cancer Health Research

ESMO 2021: Quality of Life and Long-Term Comorbidities

ESMO 2021: Enhanced Androgen Signalling Inhibition Should Be the Treatment of Choice for Treatment of mCSPC Rather than Docetaxel - Yes

ESMO 2021: Enhanced Androgen Signalling Inhibition Should Be the Treatment of Choice for Treatment of mCSPC Rather than Docetaxel - No

ESMO 2021: Are Adjuvant Immune Checkpoint Inhibitors a Standard of Care for Operable High-Risk Urothelial and Kidney Cancer? No

ESMO 2021: Are Adjuvant Immune Checkpoint Inhibitors a Standard of Care for Operable High-Risk Urothelial and Kidney Cancer? Yes

ESMO 2021: The Role of Imaging in Selecting Treatment

ESMO 2021: Evidence-Based Treatment Options in Biochemically Relapsed Prostate Cancer

1
2
3
4
5
6
7